 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Pharmacyclics, Inc.
 |
Pharmacyclics, Inc. |
 |
 |
 |
PROFILE |
 |
Pharmacyclics rides herd on the development of drugs that enhance radiation therapy, chemotherapy, and photodynamic therapy. These drug candidates, which localize in the cells targeted for treatment, are activated by light, chemicals, or X-rays and may be used to help treat cancer, cardiovascular disease, and other conditions. The development-stage firm has licensing and development agreements with the National Cancer Institute, The University of Texas, ophthalmic firm Alcon Laboratories, and imaging-agent experts Amershame (formerly Nycomed Amersham). Pharmacyclics has developed CITRA VU, a contrast agent it has licensed to E-Z-EM.
COMPETITION |
 |
Mallinckrodt Inc. (dossier)
Medical Resources, Inc. (MRIIQ)
QLT Inc. (QLTI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 1.60
1-Yr. Sales Growth: (20.0)%
Employees: 146
Revenue per employee: $10,958.90
KEY PEOPLE |
 |
Richard A. Miller
CEO
Leiv Lea
CFO
CONTACT INFO |
 |
995 E. Arques Ave.
Sunnyvale, CA 94086
US
Phone: 408-774-0330
Fax: 408-774-0340
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |